Published in Immunol Res on March 01, 2013
Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. Biomed Res Int (2015) 0.82
Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. Mod Pathol (2016) 0.75
Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer (2016) 0.75
Immunoplasticity in cutaneous melanoma: beyond pure morphology. Virchows Arch (2017) 0.75
Tbet and IL-36γ cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. Oncoimmunology (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Control of regulatory T cell development by the transcription factor Foxp3. Science (2003) 40.32
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Malignant gliomas in adults. N Engl J Med (2008) 20.54
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature (2010) 16.12
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 14.90
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A (2005) 10.89
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol (2005) 9.72
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03
Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med (1994) 8.39
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol (2008) 8.09
Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol (2001) 7.43
Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol (2007) 6.68
Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res (2005) 6.66
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol (2002) 6.60
Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother (2008) 6.55
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood (2009) 6.17
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol (2011) 6.13
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J Clin Invest (2006) 5.62
Mechanisms of suppression by suppressor T cells. Nat Immunol (2005) 5.52
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med (2009) 4.68
Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res (2001) 4.49
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43
Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev (2008) 4.36
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med (2006) 4.20
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res (2009) 4.16
All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res (2006) 4.06
Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med (2001) 3.74
Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res (2004) 3.59
Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J Immunol (2005) 3.53
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med (2005) 3.13
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A (2010) 3.12
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 3.03
Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol (2009) 3.02
L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes. J Immunol (2003) 2.91
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol (2008) 2.84
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer (1977) 2.76
Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res (2010) 2.74
Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res (2010) 2.73
Breast cancer before age 40 years. Semin Oncol (2009) 2.71
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med (2010) 2.65
Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity. Blood (2004) 2.61
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2010) 2.56
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48
Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res (2011) 2.40
Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol (2002) 2.38
Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res (2008) 2.37
Breast cancer in young women: poor survival despite intensive treatment. PLoS One (2009) 2.36
The correlation between papillary thyroid carcinoma and lymphocytic infiltration in the thyroid gland. J Clin Endocrinol Metab (1995) 2.32
Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res (2008) 2.26
Current concepts and management of glioblastoma. Ann Neurol (2011) 2.23
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate (2010) 2.22
CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol (2006) 2.18
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res (2008) 2.15
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin Oncol (2010) 1.98
Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A (2011) 1.97
Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res (1995) 1.96
CD20+ B cells: the other tumor-infiltrating lymphocytes. J Immunol (2010) 1.95
Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol (2010) 1.94
Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother (2003) 1.88
Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J Immunother (2012) 1.87
Suppression of T-cell functions by human granulocyte arginase. Blood (2006) 1.85
Immunotherapy for melanoma: current status and perspectives. J Immunother (2010) 1.72
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol (2007) 1.69
Circulating tumor antigen-specific regulatory T cells in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2007) 1.66
Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-β. Clin Cancer Res (2011) 1.61
On the dual roles and polarized phenotypes of neutrophils in tumor development and progression. Crit Rev Oncol Hematol (2011) 1.58
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol (2010) 1.53
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol (1988) 1.46
Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer (1997) 1.46
Tumour-infiltrating lymphocytes: A prognostic factor of PSA-free survival in patients with local prostate carcinoma treated by radical prostatectomy. Anticancer Res (2005) 1.45
FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood (2008) 1.45
Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) 1.45
Mechanisms of malignant glioma immune resistance and sources of immunosuppression. Gene Ther Mol Biol (2006) 1.43
The paradox of tumor-associated neutrophils: fueling tumor growth with cytotoxic substances. Cell Cycle (2010) 1.42
Early neutrophilia is associated with volume of ischemic tissue in acute stroke. Stroke (2007) 1.40
Thyroid cancer and inflammation. Mol Cell Endocrinol (2009) 1.37
Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol (2010) 1.34
Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol (1999) 1.33
Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg (2006) 1.32
The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer (2010) 1.30
Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer (2011) 1.27
Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res (2011) 1.22
Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am (2010) 1.22
Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? Clin Cancer Res (2008) 1.21
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet (2009) 8.69
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med (2012) 7.06
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
Effects of limited work hours on surgical training. J Am Coll Surg (2002) 3.82
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab (2009) 3.23
Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03
Genomic affinities of two 7,000-year-old Iberian hunter-gatherers. Curr Biol (2012) 2.67
Exacerbation of collagen-induced arthritis by oligoclonal, IL-17-producing gamma delta T cells. J Immunol (2007) 2.62
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat Med (2011) 2.12
Diagnosis of invasive lobular carcinoma in a young woman presenting with pleomorphic lobular carcinoma in situ on core biopsy. Oncology (Williston Park) (2011) 2.08
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Microphysiology of epileptiform activity in human neocortex. J Clin Neurophysiol (2008) 1.78
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid (2009) 1.73
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets. Stem Cells (2012) 1.70
CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol (2007) 1.58
Pregnancy and breast cancer: when they collide. J Mammary Gland Biol Neoplasia (2009) 1.55
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer. Anticancer Res (2012) 1.53
Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol (2006) 1.53
gammadelta T-cell receptors: functional correlations. Immunol Rev (2007) 1.50
Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg (2013) 1.50
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. Cancer (2014) 1.48
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab (2006) 1.45
Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clin Endocrinol (Oxf) (2004) 1.43
Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol (2014) 1.42
Recurrence after treatment of micropapillary thyroid cancer. Thyroid (2009) 1.41
Plasmacytoid and myeloid dendritic cells with a partial activation phenotype accumulate in lymphoid tissue during asymptomatic chronic HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.40
Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J Clin Invest (2006) 1.40
Effect of body mass index on short-term outcomes after colectomy for cancer. J Am Coll Surg (2008) 1.39
Body image in recently diagnosed young women with early breast cancer. Psychooncology (2012) 1.36
Use of baculovirus MHC/peptide display libraries to characterize T-cell receptor ligands. Immunol Rev (2006) 1.33
Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes. Cancer Res (2006) 1.25
Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice. J Immunol (2003) 1.25
Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat (2013) 1.24
Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res (2011) 1.22
Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab (2012) 1.21
Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res (2006) 1.21
A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med (2013) 1.19
Synergistic effect of a granulocyte-macrophage colony-stimulating factor-transduced tumor vaccine and systemic interleukin-2 in the treatment of murine colorectal cancer hepatic metastases. Ann Surg Oncol (2003) 1.18
Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog (2006) 1.17
Post-discharge venous thromboembolism after cancer surgery: extending the case for extended prophylaxis. Ann Surg (2011) 1.17
Fragmentation of contaminant and endogenous DNA in ancient samples determined by shotgun sequencing; prospects for human palaeogenomics. PLoS One (2011) 1.16
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res (2012) 1.14
Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer (2010) 1.13
Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab (2013) 1.13
Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab (2010) 1.13
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid (2013) 1.12
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol (2012) 1.12
Airway hyperresponsiveness through synergy of gammadelta} T cells and NKT cells. J Immunol (2007) 1.11
Dynamics of central and peripheral immunomodulation in a murine glioma model. BMC Immunol (2009) 1.11
Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab (2009) 1.11
Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. BMC Cancer (2007) 1.11
Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimeras. Blood (2002) 1.10
Outcomes after related and unrelated umbilical cord blood transplantation for hereditary bone marrow failure syndromes other than Fanconi anemia. Haematologica (2010) 1.09
Live attenuated Listeria monocytogenes effectively treats hepatic colorectal cancer metastases and is strongly enhanced by depletion of regulatory T cells. Cancer Res (2007) 1.08
Survival in sentinel lymph node-positive pediatric melanoma. J Pediatr Surg (2005) 1.08
Mobilizing the low-avidity T cell repertoire to kill tumors. Semin Cancer Biol (2007) 1.08
Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther (2004) 1.08
Hepatic complications of breast cancer. Lancet Oncol (2009) 1.07
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid (2013) 1.07
A modified tyrosinase-related protein 2 epitope generates high-affinity tumor-specific T cells but does not mediate therapeutic efficacy in an intradermal tumor model. J Immunol (2006) 1.06
Studies of lymphocyte reconstitution in a humanized mouse model reveal a requirement of T cells for human B cell maturation. J Immunol (2013) 1.06
Human intestinal lamina propria CD1c+ dendritic cells display an activated phenotype at steady state and produce IL-23 in response to TLR7/8 stimulation. J Immunol (2010) 1.05
The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol (2004) 1.05
Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid (2010) 1.04
Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg (2013) 1.03
Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2010) 1.02
Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy. Elife (2013) 1.02
Comparative hematologic analysis of uncomplicated malaria in uniquely different regions of unstable transmission in Brazil and Colombia. Am J Trop Med Hyg (2009) 1.01
Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance. Breast Cancer Res Treat (2008) 1.01
Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. J Immunol (2008) 0.99
Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer. J Clin Invest (2014) 0.98
Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg (2005) 0.98
HIV-1 infection of human intestinal lamina propria CD4+ T cells in vitro is enhanced by exposure to commensal Escherichia coli. J Immunol (2012) 0.98
gammadelta T lymphocytes-selectable cells within the innate system? J Clin Immunol (2007) 0.97
Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents. J Pediatr Surg (2005) 0.97
Pregnancy-associated breast cancer: an entity needing refinement of the definition. Cancer (2011) 0.97
Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res (2008) 0.96
Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol (2002) 0.96
Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. Cancer (2011) 0.96
Peptide vaccines prevent tumor growth by activating T cells that respond to native tumor antigens. Proc Natl Acad Sci U S A (2010) 0.96
Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2012) 0.96
Intracranial multimodal monitoring for acute brain injury: a single institution review of current practices. Neurocrit Care (2010) 0.96
Defective receptor expression and dendritic cell differentiation of monocytes in glioblastomas. Neurosurgery (2006) 0.95
In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res (2008) 0.94
Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients. Cancer Immunol Immunother (2013) 0.94
Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways Ex vivo. Retrovirology (2014) 0.93
Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol (2013) 0.92
Atypical expression of ErbB3 in myeloma cells: cross-talk between ErbB3 and the interferon-alpha signaling complex. Oncogene (2003) 0.92